Alembic Pharma

₹1092.9 8.6 | 0.8%

WEBSITE BSE:533573 NSE : ALEM PHARMA 09 Dec, 13:21

Market Cap ₹21481 Cr.

Stock P/E 34.8

P/B 4.4

Current Price ₹1092.9

Book Value ₹ 248.7

Face Value 2

52W High ₹1296.2

Dividend Yield 1.01%

52W Low ₹ 745

Edit Ratio

Alembic Pharma Research see more...

Overview Inc. Year: 2010Industry: Pharmaceuticals & Drugs

Alembic Pharmaceuticals Ltd is a pharmaceutical organisation. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company specializes in analgesic, cough anti-infective, and cold therapies. It additionally focuses on cures, including gastrointestinal, orthopedic, dermatology, cardiology, diabetes, gynecology, and ophthalmology. Its APIs consist of independent production blocks for Macrolides, non-steroidal anti-inflammatory pills (NSAIDs) and different capsules. The Company gives global and home formulations. Under home components, it offers Branded Formulations and Generic formulations. Its domestic formula include Revas H, Lactonic, Folinal, Gestofit, Roxid, Zofix, Althrocin, Tellzy AH, Glisen 1/2, Glimser 1/2, Veldrop, Azithral, Brinzemic and Neolap. Its usual formulations include Alcephin, Alcizon, Baciclox, Comeba, Furobid, Cetral, Ephedrex CD, Sicor, Worid, O Win Suspension, O win T, Silomag Gel, Pentab, Aginal AT and Pyremol.

Alembic Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Alembic Pharma Quarterly Results

#(Fig in Cr.)	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Net Sales	1262	1475	1509	1406	1486	1595	1631	1517	1562	1648
Other Income	1	0	0	1	12	10	3	4	2	17
Total Income	1263	1475	1509	1407	1498	1605	1633	1521	1564	1665
Total Expenditure	1247	1242	1260	1194	1287	1387	1364	1257	1325	1409
Operating Profit	16	233	249	213	210	218	269	264	239	256
Interest	9	12	15	14	14	16	15	11	13	19
Depreciation	67	68	67	74	66	68	69	69	69	71
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	13
Profit Before Tax	-60	153	168	125	130	135	185	183	157	180
Provision for Tax	-2	18	33	-36	9	-2	4	5	22	27
Profit After Tax	-59	135	136	161	121	137	181	179	134	152
Adjustments	-7	-2	-14	-8	-0	-1	-0	-0	0	1
Profit After Adjustments	-66	133	122	153	121	137	180	178	135	153
Adjusted Earnings Per Share	-3.4	6.8	6.2	7.8	6.1	6.9	9.2	9.1	6.9	7.8

Alembic Pharma Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	1863	2056	3166	3135	3131	3935	4606	5393	5306	5653	6229	6358
Other Income	4	12	9	3	35	27	14	87	50	3	29	26
Total Income	1868	2068	3175	3137	3166	3962	4620	5481	5356	5656	6258	6383
Total Expenditure	1506	1661	2161	2520	2516	3079	3392	3913	4432	4945	5296	5355
Operating Profit	361	407	1014	617	650	883	1228	1568	925	711	962	1028
Interest	10	4	5	5	3	18	27	16	18	50	56	58
Depreciation	40	44	72	83	105	115	157	183	287	275	273	278
Exceptional Income / Expenses	0	0	0	0	0	0	-44	0	0	0	0	13
Profit Before Tax	311	359	936	529	541	749	1000	1368	625	355	632	705
Provision for Tax	75	76	216	122	120	157	199	253	104	13	16	58
Profit After Tax	236	283	720	407	421	593	801	1115	521	342	616	646
Adjustments	0	0	0	-4	-8	-8	28	32	0	0	0	1
Profit After Adjustments	236	283	720	403	413	584	829	1147	521	342	616	646
Adjusted Earnings Per Share	12.5	15	38.2	21.4	21.9	31	44	58.3	26.5	17.4	31.3	33

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	10%	5%	10%	13%
Operating Profit CAGR	35%	-15%	2%	10%
PAT CAGR	80%	-18%	1%	10%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	43%	11%	15%	10%
ROE Average	13%	10%	17%	26%
ROCE Average	13%	11%	16%	27%

Alembic Pharma Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	676	885	1597	1902	2220	2719	3219	5067	5238	4370	4818
Minority's Interest	0	0	0	0	0	-1	-29	0	0	0	0
Borrowings	52	19	0	0	500	499	887	200	0	0	0
Other Non-Current Liabilities	42	54	84	94	76	71	160	161	162	52	3
Total Current Liabilities	603	908	944	814	1267	1664	1954	1533	1831	1641	1520
Total Liabilities	1372	1865	2626	2811	4064	4952	6192	6961	7230	6064	6341
Fixed Assets	397	547	708	799	993	1158	1552	1788	1798	2398	2547
Other Non-Current Assets	119	204	209	517	1123	1662	1974	2269	2458	751	651
Total Current Assets	857	1115	1708	1494	1948	2132	2665	2904	2975	2914	3144
Total Assets	1372	1865	2626	2811	4064	4952	6192	6961	7230	6064	6341

Alembic Pharma Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	16	24	23	439	153	84	199	72	98	61	75
Cash Flow from Operating Activities	240	172	948	329	312	812	449	1463	552	724	803
Cash Flow from Investing Activities	-81	-256	-307	-486	-884	-756	-732	-839	-372	-448	-321
Cash Flow from Financing Activities	-151	87	-224	-129	503	59	155	-597	-217	-262	-438
Net Cash Inflow / Outflow	8	3	417	-286	-69	115	-128	27	-37	14	45
Closing Cash & Cash Equivalent	24	27	439	153	84	199	72	98	61	75	120

Alembic Pharma Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	12.49	15.01	38.2	21.39	21.89	31	43.97	58.33	26.5	17.4	31.33
CEPS(Rs)	14.64	17.35	42.03	25.99	27.92	37.55	50.82	66.05	41.09	31.41	45.2
DPS(Rs)	3	3.5	4	4	4	5.5	10	14	10	8	11
Book NAV/Share(Rs)	35.84	46.93	84.74	100.92	117.78	144.24	170.79	257.8	266.47	222.36	245.14
Core EBITDA Margin(%)	19.08	19.08	31.75	19.61	19.65	21.75	26.36	27.44	16.48	12.53	14.97
EBIT Margin(%)	17.16	17.52	29.74	17.05	17.4	19.51	22.3	25.66	12.12	7.16	11.05
Pre Tax Margin(%)	16.6	17.34	29.57	16.88	17.29	19.04	21.71	25.37	11.79	6.27	10.14
PAT Margin (%)	12.59	13.65	22.74	12.98	13.44	15.06	17.38	20.67	9.82	6.05	9.89
Cash Profit Margin (%)	14.75	15.79	25.02	15.63	16.81	17.99	20.8	24.07	15.22	10.92	14.26
ROA(%)	18.79	17.47	32.07	14.97	12.25	13.15	14.37	16.95	7.34	5.15	9.93
ROE(%)	39.97	36.24	58.02	23.25	20.42	24	26.97	26.91	10.11	7.12	13.4
ROCE(%)	43.54	37.54	65.86	28.87	22.15	22.66	23.3	26.28	11.25	7.44	13.42
Receivable days	49.38	55.91	41.02	40.13	50.43	47.09	53.64	41.06	39.75	59.84	60.69
Inventory Days	56.34	61.11	54.91	70.01	79.67	78.91	85.38	90.48	106.49	99.6	91.38
Payable days	153.8	174.95	197.26	219.27	259.49	258.05	223.04	187.92	173.51	148.04	150.62
PER(x)	22.72	30.2	15.72	29.16	25.12	17.11	12.14	16.55	27.97	28.5	31.35
Price/Book(x)	7.92	9.66	7.09	6.18	4.67	3.68	3.12	3.74	2.78	2.23	4.01
Dividend Yield(%)	1.06	0.77	0.67	0.64	0.73	1.04	1.87	1.45	1.35	1.61	1.12
EV/Net Sales(x)	2.92	4.27	3.47	3.73	3.51	2.78	2.55	3.59	2.85	1.82	3.15
EV/Core EBITDA(x)	15.04	21.56	10.83	18.93	16.89	12.37	9.55	12.35	16.37	14.49	20.39
Net Sales Growth(%)	22.55	10.35	53.98	-0.99	-0.12	25.68	17.06	17.1	-1.62	6.54	10.19
EBIT Growth(%)	39.37	13.04	159.47	-43.25	1.94	40.95	33.77	34.77	-53.53	-37.06	69.98
PAT Growth(%)	42.51	20.05	154.68	-43.49	3.44	40.78	35.11	39.23	-53.27	-34.35	80.07
EPS Growth(%)	42.51	20.13	154.52	-44.01	2.35	41.62	41.83	32.66	-54.56	-34.35	80.07
Debt/Equity(x)	0.16	0.3	0.07	0.05	0.32	0.42	0.54	0.1	0.12	0.15	0.09
Current Ratio(x)	1.42	1.23	1.81	1.84	1.54	1.28	1.36	1.89	1.63	1.78	2.07
Quick Ratio(x)	0.91	0.81	1.24	1.06	0.96	0.7	0.76	0.93	0.75	0.88	0.99
Interest Cover(x)	30.87	95.3	173.4	102.16	160.2	41.7	37.81	86.4	36.27	8.07	12.24
Total Debt/Mcap(x)	0.02	0.03	0.01	0.01	0.07	0.11	0.17	0.03	0.04	0.07	0.02

Alembic Pharma Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61
FII	5.94	5.32	4.99	4.55	4.34	4.5	4.52	4.46	4.32	3.94
DII	12.15	12.54	12.76	13.31	13.64	14.22	14.5	15.39	15.47	16.05
Public	12.3	12.53	12.65	12.53	12.4	11.67	11.37	10.54	10.6	10.4
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68
FII	1.17	1.05	0.98	0.89	0.85	0.89	0.89	0.88	0.85	0.77
DII	2.39	2.47	2.51	2.62	2.68	2.79	2.85	3.02	3.04	3.15
Public	2.42	2.46	2.49	2.46	2.44	2.29	2.23	2.07	2.08	2.04
Others	0	0	0	0	0	0	0	0	0	0
Total	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66

Pros

Company is almost debt free.

Cons

Company has a low return on equity of 10% over the last 3 years.
Debtor days have increased from 148.04 to 150.62days.
Stock is trading at 4.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alembic Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Alembic Pharma

Add Watchlist

Alembic Pharma Research see more...

Overview Inc. Year: 2010Industry: Pharmaceuticals & Drugs

Alembic Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Alembic Pharma Quarterly Results

Alembic Pharma Profit & Loss

Growth Rates

Alembic Pharma Balance Sheet

Alembic Pharma Cash Flow

Alembic Pharma Ratios

Alembic Pharma Shareholding Pattern

Alembic Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!